Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cream Vehicle Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

NCT04378569
View directory record Official record
Conditions
Chronic Hand Eczema
Interventions
ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Beverly Hills, California • Encino, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women

NCT01816139
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
Vehicle, WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
48
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 19, 2026, 5:10 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

NCT03539601
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 19, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT07257029
View directory record Official record
Conditions
Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia, Vulvary Pain Disorders, Neuroproliferative Vestibulodynia, Mast Cell-mediated Neuroinflammation, Instertional Dyspareunia
Interventions
Ketotifen Fumarate 0.25% Cream, Placebo (Vehicle Cream)
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

NCT05675501
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Encapsulated Benzoyl Peroxide Cream
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

NCT00539929
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
E6201 0.005%, E6201 0.01%, E6201 0.03%, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Hot Springs, Arkansas • San Diego, California • Boise, Idaho + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers

NCT05279495
View directory record Official record
Conditions
Photoaging
Interventions
In a double-blinded fashion, 250 mg CANNAXR cream, Topical VEHICLE cream
Device
Lead sponsor
MINO Labs, LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

NCT06063473
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
762 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 2 Interventional

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01241331
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100, Vehicle cream
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • Oceanside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 19, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional

Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction

NCT01810575
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
WC3036-11F/Alprostadil in Vehicle 2.5%, WC3036-12F/Alprostadil in Vehicle 0.5%, WC3036-13P/Vehicle Only 0.5%
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Purchase, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

NCT05089708
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream, Trifarotene Vehicle Cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
13 Years to 35 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Fountain Valley, California • Fremont, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pediatric Subjects With Tinea Corporis

NCT02227290
View directory record Official record
Conditions
Tinea Corporis
Interventions
Naftin Cream, Placebo Cream
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
14
States / cities
Tucson, Arizona • Encino, California • Fremont, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

NCT03956355
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tapinarof, Vehicle Cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

NCT04921969
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.

NCT07546214
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

NCT02411162
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

NCT03445013
View directory record Official record
Conditions
Psoriasis
Interventions
SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Boise, Idaho • Austin, Texas • College Station, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 19, 2026, 5:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

NCT03954236
View directory record Official record
Conditions
Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Interventions
topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

NCT00115154
View directory record Official record
Conditions
Keratosis
Interventions
Aldara (imiquimod) cream, 5%
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
18
States / cities
Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2007 · Synced Sep 19, 2026, 5:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

NCT03427554
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 19, 2026, 5:10 AM EDT